{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:10:55Z","timestamp":1780539055838,"version":"3.54.1"},"reference-count":166,"publisher":"Cambridge University Press (CUP)","issue":"10","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":3689,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS spectr."],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A substantial number of patients with panic disorder and agoraphobia may remain symptomatic after standard treatment (including selective serotonin reuptake inhibitors, tricyclic antidepressants, benzodiazepines, or irreversible monamine oxidase inhibitors). In this review, recommendations for the treatment of patients with panic disorder and agoraphobia who do not respond to these drugs are provided. Nonresponse to drug treatment could be defined as a failure to achieve a 50% reduction on a standard rating scale after a minimum of 6 weeks of treatment in adequate dose. When initial treatments have failed, the medication should be changed to other standard treatments. In further attempts at treatment, drugs should be used that have shown promising results in preliminary studies, such as venlafaxine. Combination treatments may be used, such as the combination of an selective serotonin reuptake inhibitor and a benzodiazepine. Psychological treatments such as cognitive-behavioral therapy have to be considered in all patients, regardless whether they are nonresponders or not. According to existing studies, a combination of pharmacologic treatment with cognitive-behavioral therapy can be recommended.<\/jats:p>","DOI":"10.1017\/s1092852900022379","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T04:39:50Z","timestamp":1470112790000},"page":"725-739","source":"Crossref","is-referenced-by-count":41,"title":["Treatment-Resistant Panic Disorder"],"prefix":"10.1017","volume":"9","author":[{"given":"Borwin","family":"Bandelow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckart","family":"R\u00fcther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900022379_ref113","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900018617"},{"key":"S1092852900022379_ref042","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(89)90009-8"},{"key":"S1092852900022379_ref112","first-page":"134","article-title":"Panic disorder: treatment with valproate","volume":"55","author":"Woodman","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"S1092852900022379_ref108","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200010000-00009"},{"key":"S1092852900022379_ref105","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1176\/ajp.152.7.1084","article-title":"Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder","volume":"152","author":"Benjamin","year":"1995","journal-title":"Am J Psychiatry"},{"key":"S1092852900022379_ref097","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1993.tb03405.x"},{"key":"S1092852900022379_ref096","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0107"},{"key":"S1092852900022379_ref093","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.1.15"},{"key":"S1092852900022379_ref086","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.49.4.318"},{"key":"S1092852900022379_ref090","first-page":"580","article-title":"Drug treatment of panic disorder: the com-parative efficacy of imipramine, alprazolam, and trazodone","volume":"47","author":"Charney","year":"1986","journal-title":"J Clin Psychiatry"},{"key":"S1092852900022379_ref001","first-page":"49","volume-title":"Handbook on Depression and Anxiety","author":"Bandelow","year":"2003"},{"key":"S1092852900022379_ref081","doi-asserted-by":"publisher","DOI":"10.1017\/S109285290000691X"},{"key":"S1092852900022379_ref075","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.7.681"},{"key":"S1092852900022379_ref047","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(88)90054-7"},{"key":"S1092852900022379_ref074","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199912002-00004"},{"key":"S1092852900022379_ref080","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200206000-00008"},{"key":"S1092852900022379_ref072","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psychotherapy.1982.36.3.358"},{"key":"S1092852900022379_ref071","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291798006540"},{"key":"S1092852900022379_ref002","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0317"},{"key":"S1092852900022379_ref079","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.174.3.205"},{"key":"S1092852900022379_ref070","first-page":"69","article-title":"Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology","volume":"6","author":"Nelson","year":"1999","journal-title":"Can J Clin Pharmacol"},{"key":"S1092852900022379_ref069","first-page":"281","article-title":"Benzodiazepine dependence","volume":"51","author":"Livingston","year":"1994","journal-title":"Br J Hosp Med"},{"key":"S1092852900022379_ref146","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.167.5.635"},{"key":"S1092852900022379_ref151","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.144.3.276"},{"key":"S1092852900022379_ref062","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1014489"},{"key":"S1092852900022379_ref061","first-page":"418","article-title":"Benzodiazepine treatment of panic disorder: a com-parison of alprazolam and lorazepam","volume":"50","author":"Charney","year":"1989","journal-title":"J Clin Psychiatry"},{"key":"S1092852900022379_ref059","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199710000-00008"},{"key":"S1092852900022379_ref087","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0606"},{"key":"S1092852900022379_ref126","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(93)90026-Q"},{"key":"S1092852900022379_ref094","first-page":"667","article-title":"Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study","volume":"32","author":"Pollack","year":"1996","journal-title":"Psychopharmacol Bull"},{"key":"S1092852900022379_ref076","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1980.01780140053006"},{"key":"S1092852900022379_ref052","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800290027004"},{"key":"S1092852900022379_ref133","first-page":"116","article-title":"Agoraphobia: behavioral and pharmacological treatment (n=49)","volume":"19","author":"Mavissakalian","year":"1983","journal-title":"Psychopharmacol Bull"},{"key":"S1092852900022379_ref082","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n1006"},{"key":"S1092852900022379_ref066","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(90)90046-S"},{"key":"S1092852900022379_ref051","volume-title":"International Classification of Diseases","year":"1991"},{"key":"S1092852900022379_ref092","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199004000-00006"},{"key":"S1092852900022379_ref121","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(05)80266-7"},{"key":"S1092852900022379_ref118","first-page":"105","volume-title":"Treatment of panic disor-der. A consensus development conference","author":"Barlow","year":"1994"},{"key":"S1092852900022379_ref048","first-page":"251","article-title":"Superiority of clomipramine over imi-pramine in the treatment of panic disorder: a placebo-controlled trial","volume":"12","author":"Modigh","year":"1992","journal-title":"J Clin Psychopharmacol"},{"key":"S1092852900022379_ref044","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.160.2.191"},{"key":"S1092852900022379_ref043","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199002000-00002"},{"key":"S1092852900022379_ref088","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199503000-00006"},{"key":"S1092852900022379_ref040","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1980.01780140065007"},{"key":"S1092852900022379_ref039","doi-asserted-by":"publisher","DOI":"10.1007\/BF02193476"},{"key":"S1092852900022379_ref049","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1997.tb00389.x"},{"key":"S1092852900022379_ref006","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n1206"},{"key":"S1092852900022379_ref036","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.9.1189"},{"key":"S1092852900022379_ref030","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.1.36"},{"key":"S1092852900022379_ref164","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(05)80282-5"},{"key":"S1092852900022379_ref027","doi-asserted-by":"publisher","DOI":"10.1002\/anxi.3070010608"},{"key":"S1092852900022379_ref026","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.11.1570"},{"key":"S1092852900022379_ref024","first-page":"135","article-title":"A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia","volume":"32","author":"Bakish","year":"1996","journal-title":"Psychopharmacol Bull"},{"key":"S1092852900022379_ref020","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1077(199908)14:6<435::AID-HUP109>3.0.CO;2-B"},{"key":"S1092852900022379_ref089","first-page":"167","article-title":"A comparison of alprazo-lam and imipramine in the treatment of agoraphobia and panic disorder","volume":"22","author":"Rizley","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"S1092852900022379_ref077","doi-asserted-by":"publisher","DOI":"10.1007\/PL00014164"},{"key":"S1092852900022379_ref015","unstructured":"European Medices Agency web site. Committee for Proprietary Medicinal Products. Note for guidance on the clinical investigation of medicinal products indicated for the treatment of panic disorder. http:\/\/www.emea.eu.int\/pdfs\/human\/ewp\/428002en.pdf2003."},{"key":"S1092852900022379_ref019","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.170.6.549"},{"key":"S1092852900022379_ref129","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(05)80266-7"},{"key":"S1092852900022379_ref091","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470050209"},{"key":"S1092852900022379_ref135","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(88)80035-2"},{"key":"S1092852900022379_ref011","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(03)00043-0"},{"key":"S1092852900022379_ref021","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1107"},{"key":"S1092852900022379_ref115","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.162.6.776"},{"key":"S1092852900022379_ref117","volume-title":"Anxiety Disorders and Phobias: A Cognitive Perspective","author":"Beck","year":"1985"},{"key":"S1092852900022379_ref156","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200010000-00011"},{"key":"S1092852900022379_ref148","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.143.4.348"},{"key":"S1092852900022379_ref114","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790020047004"},{"key":"S1092852900022379_ref063","first-page":"458","article-title":"Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study","volume":"47","author":"Dunner","year":"1986","journal-title":"J Clin Psychiatry"},{"key":"S1092852900022379_ref023","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199310000-00004"},{"key":"S1092852900022379_ref029","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.167.3.374"},{"key":"S1092852900022379_ref022","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245749"},{"key":"S1092852900022379_ref032","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n1205"},{"key":"S1092852900022379_ref018","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(1999)9:3<107::AID-DA2>3.0.CO;2-T"},{"key":"S1092852900022379_ref055","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1991.tb03097.x"},{"key":"S1092852900022379_ref058","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0907"},{"key":"S1092852900022379_ref041","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790020019002"},{"key":"S1092852900022379_ref099","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198302000-00006"},{"key":"S1092852900022379_ref046","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-12982"},{"key":"S1092852900022379_ref037","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.00498.x"},{"key":"S1092852900022379_ref013","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(02)00010-9"},{"key":"S1092852900022379_ref102","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1984.01790140077009"},{"key":"S1092852900022379_ref147","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1176\/ajp.152.5.683","article-title":"Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone","volume":"152","author":"de Beurs","year":"1995","journal-title":"Am J Psychiatry"},{"key":"S1092852900022379_ref054","first-page":"349","article-title":"Diazepam versus alprazolam for the treatment of panic disorder","volume":"57","author":"Noyes","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"S1092852900022379_ref103","first-page":"344","article-title":"A controlled study of al-prazolam and propranolol in panic-disordered and agoraphobic outpatients","volume":"1","author":"Ravaris","year":"1991","journal-title":"J Clin Psychopharmacol"},{"key":"S1092852900022379_ref064","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1990.01810220024003"},{"key":"S1092852900022379_ref161","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200302000-00015"},{"key":"S1092852900022379_ref166","first-page":"481","article-title":"Clomi-pramine in the treatment of agoraphobic inpatients resistant to behavioral therapy","volume":"54","author":"Hoffart","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"S1092852900022379_ref031","first-page":"53","article-title":"Treatment of panic disorder: focus on paroxetine","volume":"37","author":"Pollack","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"S1092852900022379_ref109","doi-asserted-by":"publisher","DOI":"10.3109\/10401239909147053"},{"key":"S1092852900022379_ref100","first-page":"66","article-title":"Bupropion sustained release for panic disorder","volume":"37","author":"Simon","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"S1092852900022379_ref067","first-page":"S109","article-title":"Benzodiazepines for the treatment of panic disorder and general-ized anxiety disorder: clinical issues and future directions","volume":"38","author":"Bradwejn","year":"1993","journal-title":"Can J Psychiatry"},{"key":"S1092852900022379_ref007","doi-asserted-by":"publisher","DOI":"10.1177\/026988110101500103"},{"key":"S1092852900022379_ref122","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.58.1.77"},{"key":"S1092852900022379_ref110","doi-asserted-by":"publisher","DOI":"10.1177\/070674379003500309"},{"key":"S1092852900022379_ref139","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.68.6.947"},{"key":"S1092852900022379_ref045","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800290073009"},{"key":"S1092852900022379_ref085","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1176\/ajp.149.8.1053","article-title":"Protective effects of imiptamine maintenance treatment in panic disorder with agoraphobia","volume":"149","author":"Mavissakalian","year":"1992","journal-title":"Am J Psychiatry"},{"key":"S1092852900022379_ref107","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(1999)10:3<137::AID-DA8>3.0.CO;2-7"},{"key":"S1092852900022379_ref014","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.68.1.13"},{"key":"S1092852900022379_ref068","first-page":"1398","article-title":"Use of benzodiazepines in anxiety disorders","volume":"13","author":"Shader","year":"1993","journal-title":"New Engl J Med"},{"key":"S1092852900022379_ref057","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199404000-00005"},{"key":"S1092852900022379_ref025","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.6.514"},{"key":"S1092852900022379_ref008","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0404"},{"key":"S1092852900022379_ref003","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1993.01820130046008"},{"key":"S1092852900022379_ref084","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.174.3.213"},{"key":"S1092852900022379_ref083","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2001.00263.x"},{"key":"S1092852900022379_ref073","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1176\/ajp.150.10.1485","article-title":"Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder","volume":"150","author":"Otto","year":"1993","journal-title":"Am J Psychiatry"},{"key":"S1092852900022379_ref034","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.173.1.54"},{"key":"S1092852900022379_ref106","first-page":"245","article-title":"An open-label trial of nefazodone in high comorbidity panic disorder","volume":"57","author":"DeMartinis","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"S1092852900022379_ref137","doi-asserted-by":"publisher","DOI":"10.1007\/s001150050709"},{"key":"S1092852900022379_ref028","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1077(199908)14:6<429::AID-HUP108>3.0.CO;2-3"},{"key":"S1092852900022379_ref004","doi-asserted-by":"publisher","DOI":"10.1002\/da.1053"},{"key":"S1092852900022379_ref010","doi-asserted-by":"publisher","DOI":"10.1159\/000285045"},{"key":"S1092852900022379_ref095","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(03)92178-X"},{"key":"S1092852900022379_ref116","first-page":"32","article-title":"Cognitive-behavioral therapy for panic disorder: current status","volume":"58","author":"Barlow","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"S1092852900022379_ref098","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198808000-00033"},{"key":"S1092852900022379_ref119","first-page":"121","volume-title":"Treatment of panic disorder: A Consensus Development Conference","author":"Clark","year":"1994"},{"key":"S1092852900022379_ref060","first-page":"69","article-title":"Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder","volume":"52","author":"Tesar","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"S1092852900022379_ref120","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(89)80073-5"},{"key":"S1092852900022379_ref123","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.62.4.865"},{"key":"S1092852900022379_ref124","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(93)90036-T"},{"key":"S1092852900022379_ref153","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(05)80367-3"},{"key":"S1092852900022379_ref128","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(95)00063-1"},{"key":"S1092852900022379_ref131","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1176\/ajp.149.6.778","article-title":"A crossover study of focused cognitive therapy for panic disorder","volume":"149","author":"Beck","year":"1992","journal-title":"Am J Psychiatry"},{"key":"S1092852900022379_ref053","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199204000-00004"},{"key":"S1092852900022379_ref012","doi-asserted-by":"publisher","DOI":"10.1159\/000067188"},{"key":"S1092852900022379_ref132","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790020047004"},{"key":"S1092852900022379_ref136","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950050055006"},{"key":"S1092852900022379_ref138","doi-asserted-by":"publisher","DOI":"10.1037\/0033-3204.27.2.210"},{"key":"S1092852900022379_ref140","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.65.6.1026"},{"key":"S1092852900022379_ref141","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.5.603"},{"key":"S1092852900022379_ref142","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(85)90011-7"},{"key":"S1092852900022379_ref143","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.164.6.759"},{"key":"S1092852900022379_ref145","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01552-4"},{"key":"S1092852900022379_ref005","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(99)90075-5"},{"key":"S1092852900022379_ref149","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830080041008"},{"key":"S1092852900022379_ref150","doi-asserted-by":"publisher","DOI":"10.1002\/da.10084"},{"key":"S1092852900022379_ref160","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.4.659-a"},{"key":"S1092852900022379_ref152","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1176\/ajp.143.9.1106","article-title":"Two-year follow-up exposure and imipramine treatment of agoraphobia","volume":"143","author":"Mavissakalian","year":"1986","journal-title":"Am J Psychiatry"},{"key":"S1092852900022379_ref154","volume-title":"Panic and Agoraphobia Scale (PAS)","author":"Bandelow","year":"1999"},{"key":"S1092852900022379_ref155","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.11.1571"},{"key":"S1092852900022379_ref157","first-page":"66","article-title":"Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients","volume":"55","author":"Tiffon","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"S1092852900022379_ref158","first-page":"78","article-title":"Sodium valproate and clonazepam for treatment-resistant panic disorder","volume":"17","author":"Ontiveros","year":"1992","journal-title":"J Psychiatry Neurosci"},{"key":"S1092852900022379_ref065","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1990.01810220015002"},{"key":"S1092852900022379_ref017","first-page":"1","article-title":"Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Psychiatric Association","volume":"155","year":"1998","journal-title":"Am J Psychiatry"},{"key":"S1092852900022379_ref159","doi-asserted-by":"publisher","DOI":"10.1177\/070674378603100410"},{"key":"S1092852900022379_ref162","doi-asserted-by":"publisher","DOI":"10.1177\/02698811030173009"},{"key":"S1092852900022379_ref165","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0904"},{"key":"S1092852900022379_ref056","doi-asserted-by":"publisher","DOI":"10.1007\/BF01182877"},{"key":"S1092852900022379_ref144","first-page":"150","article-title":"Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care","volume":"47","author":"Sharp","year":"1997","journal-title":"Br J Gen Pract"},{"key":"S1092852900022379_ref035","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.55.11.1010"},{"key":"S1092852900022379_ref134","first-page":"117","article-title":"Agoraphobia\u2014relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine","volume":"47","author":"Mavissakalian","year":"1986","journal-title":"J Clin Psychiatry"},{"key":"S1092852900022379_ref050","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"S1092852900022379_ref111","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(93)90010-B"},{"key":"S1092852900022379_ref163","first-page":"200","article-title":"Cognitive behavior therapy for treatment-refractory panic disorder","volume":"55","author":"Pollack","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"S1092852900022379_ref130","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.19.2529"},{"key":"S1092852900022379_ref078","doi-asserted-by":"publisher","DOI":"10.1007\/PL00014163"},{"key":"S1092852900022379_ref009","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7967(03)00157-8"},{"key":"S1092852900022379_ref125","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(94)00061-N"},{"key":"S1092852900022379_ref127","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.63.5.823"},{"key":"S1092852900022379_ref104","doi-asserted-by":"crossref","first-page":"164A","DOI":"10.1016\/0006-3223(90)90356-7","article-title":"Divalproex sodium's antipanic effect in panic disorder: a placebo-controlled study","volume":"27","author":"Lum","year":"1990","journal-title":"Biol Psychiatry"},{"key":"S1092852900022379_ref101","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198902000-00005"},{"key":"S1092852900022379_ref033","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1997.tb00388.x"},{"key":"S1092852900022379_ref038","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050357"},{"key":"S1092852900022379_ref016","doi-asserted-by":"publisher","DOI":"10.3109\/15622970209150621"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900022379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T20:09:34Z","timestamp":1557173374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900022379\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":166,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S1092852900022379"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900022379","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}